Level Changes and Clinical Significance of Procalcitonin and N-terminal pro-B-type Natriuretic Peptide in Patients with Acute Exacerbation of Chronic Pulmonary Heart Disease
CAI Qiu-yan, CHEN Jing
Huai'an TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Huaian city, Jiangsu Province,223001,China
Abstract【Objective】 To explore clinical relationship of procalcitonin (PCT) and N-terminal pro-B-type natriureticpeptide (NT-proBNP) with the severity of acute exacerbation of chronic pulmonary heart disease (AECPHD). 【Methods】 Patients with chronic pulmonary heart disease (n=35, the CPHD group) and with AECPHD (n=32), the AECPDH group) were selected for the study. All were treated routinely according to clinical guidelines. Sputum specimens were collected for bacterial quantitative culture before treatment. Levels of PCT and NT-proBNP in patients with AECPHD and CPHD were measured before and after treatment. 【Results】 After treatment, the plasma PCT and NT-proBNP levels of the two groups were lower than before treatment, while PCT and NT-proBNP levels in patients with AECPHD were significantly higher than those in patients with CPHD. The difference was statistically significant (P<0.05). The positive rate of sputum culture (PPM ≥ 107 CFU/mL) in patients with AECPHD was 28.13% (9/32), which was higher than that in patients with CPHD 8.57% (3/32, P<0.05). 【Conclusion】 PCT and NT-proBNP levels can be used as potential indicators for the severity and treatment in patients with AECPHD.
CAI Qiu-yan,CHEN Jing. Level Changes and Clinical Significance of Procalcitonin and N-terminal pro-B-type Natriuretic Peptide in Patients with Acute Exacerbation of Chronic Pulmonary Heart Disease[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(5): 724-726.
[1] Wu Ri-na,Yang Jing-ping.Chronic obstructive pulmonary disease(COPD) respiratory failure of pulmonary heart disease with acid-base[J].J Clin Pulmon Med,2010,15 (6): 759-760. [2] Li HX,Liu ZM,Zhao SJ,et al.Measuring both procalcitonin and C-reactive protein for diagnosis of sepsis in critically ill patients[J].J Int Med Res,2014,42(4):1050-1059. [3] Yetkin O,Aksoy Y,Turhan H,et al.Value of plasma BNP levels as a prognostic marker in lung and heart disorders[J].Tuberk Toraks,2007,55(3):225-230. [4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)(一)[J].全科医学临床与教育, 2013, 11(5): 484-491. [5] Wacker C,Prkno A,Brunkhorst FM,et al.Procalcitonin as a diagnostic marker for sepsis:a systematic review and meta-analysis[J].Lancet Infect Dis,2013,13(5):426-435. [6] Leli C.Utility of brain natriuretic peptide as prognostic marker in community-acquired pneumonia and chronic obstructive pulmonary disease exacerbation patients presenting to the emergency department[J].Infez Med,2011,19(4):235-240. [7] Sakamoto D,Sakamoto S,Kanda T.Validation of circulating BNP level>1000 pg/ml in all-cause mortality:a retrospective study[J].J Int Med Res,2015,43(4):583-591. [8] Bernal V,Pascual I,Esquivias P,et al.N-terminal brain natriuret-ic peptide as a diagnostic test in cirrhotic patients with pulmonaryarterial hypertension [J].Transplant Proceed,2009, 41(3) : 987-988. [9] Leuchte HH,Holzapfel M,Baumgartner RA,et al.Clinical significance of brain natriuretic peptide in primary pulmonary hypertension[J].J Am Coll Cardiol,2004,43(5) : 764-770. [10] Andreassen AK, Wergeland R. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension [J].Am J Cardiol,2006,98(4):525-529.
2020, Vol. 37 
